TY - JOUR
T1 - Inverse Association Between Fatty Liver at Baseline Ultrasonography and Remission of Type 2 Diabetes Over a 2-Year Follow-up Period
AU - Yamazaki, Hajime
AU - Wang, Jui
AU - Tauchi, Shinichi
AU - Dohke, Mitsuru
AU - Hanawa, Nagisa
AU - Katanuma, Akio
AU - Saisho, Yoshifumi
AU - Kamitani, Tsukasa
AU - Fukuhara, Shunichi
AU - Yamamoto, Yosuke
N1 - Funding Information:
The authors thank Keita Numata, Toru Yusa, and Megumi Sato of Keijinkai Maruyama Clinic. They also thank Joseph Green for suggestions and comments on earlier versions of this manuscript. Hajime Yamazaki (Conceptualization: Lead; Formal analysis: Lead; Methodology: Lead; Project administration: Lead; Writing ? original draft: Lead; Writing ? review & editing: Lead) Jui Wang (Methodology: Equal; Writing ? review & editing: Equal) Shinichi Tauchi (Investigation: Equal; Writing ? review & editing: Equal) Mitsuru Dohke (Investigation: Equal; Writing ? review & editing: Equal) Nagisa Hanawa (Investigation: Equal; Writing ? review & editing: Equal) Akio Katanuma (Writing ? review & editing: Equal) Yoshifumi Saisho (Writing ? review & editing: Equal) Tsukasa Kamitani (Writing ? review & editing: Equal) Shunichi Fukuhara (Writing ? review & editing: Equal) Yosuke Yamamoto (Conceptualization: Equal; Methodology: Equal; Writing ? review & editing: Equal)
Publisher Copyright:
© 2021 AGA Institute
PY - 2021/3
Y1 - 2021/3
N2 - Background & Aims: Improvement of fatty liver may be required for remission of type-2 diabetes. However, there is no longitudinal evidence on whether fatty liver reduces the chances for remission of type-2 diabetes. We investigated the association between fatty liver and remission of type-2 diabetes (the primary analysis), and also the association between improvement of fatty liver and remission of type-2 diabetes (the secondary analysis). Methods: We collected data from 66961 people who underwent screening for type-2 diabetes from 2008 through 2016 at a single center in Japan. The primary analysis included 2567 patients with type-2 diabetes without chronic renal failure or a history of hemodialysis who underwent ultrasonography to detect fatty liver, all of whom had follow-up testing, including blood testing, for a median 24.5 months after the baseline ultrasonography. The secondary analysis included 1833 participants with fatty liver at baseline who underwent a second ultrasonography, and participants who had fatty liver at baseline but not at the second visit were considered to have had improvement of fatty liver. Remission of type-2 diabetes was defined as a fasting plasma glucose level below 126 mg/dL and an HbA1c level below 6.5% for more than 6 months without anti-diabetic drugs. Odds ratios (ORs) of remission of type-2 diabetes were estimated using logistic-regression models. Results: A lower proportion of patients who had fatty liver detected by ultrasonography at baseline (8.7%, 167/1910) had remission of type-2 diabetes during the follow-up period than patients without fatty liver (13.1%, 86/657). Fatty liver at baseline was associated with a lower odds of remission of type-2 diabetes (multivariable-adjusted OR, 0.51; 95% CI, 0.37–0.72). A higher proportion of patients who had improvement of fatty liver had remission of type-2 diabetes (21.1%, 32/152) than patients with no improvement of fatty liver (7.7%, 129/1681). Improvement of fatty liver was associated with a higher odds of remission of type-2 diabetes (multivariable-adjusted OR, 3.08; 95% CI, 1.94–4.88). Conclusions: Over a follow-up period of approximate 2 years, remission of type-2 diabetes was less common in people with fatty liver detected by ultrasonography, and improvement of fatty liver was independently associated with type-2 diabetes remission.
AB - Background & Aims: Improvement of fatty liver may be required for remission of type-2 diabetes. However, there is no longitudinal evidence on whether fatty liver reduces the chances for remission of type-2 diabetes. We investigated the association between fatty liver and remission of type-2 diabetes (the primary analysis), and also the association between improvement of fatty liver and remission of type-2 diabetes (the secondary analysis). Methods: We collected data from 66961 people who underwent screening for type-2 diabetes from 2008 through 2016 at a single center in Japan. The primary analysis included 2567 patients with type-2 diabetes without chronic renal failure or a history of hemodialysis who underwent ultrasonography to detect fatty liver, all of whom had follow-up testing, including blood testing, for a median 24.5 months after the baseline ultrasonography. The secondary analysis included 1833 participants with fatty liver at baseline who underwent a second ultrasonography, and participants who had fatty liver at baseline but not at the second visit were considered to have had improvement of fatty liver. Remission of type-2 diabetes was defined as a fasting plasma glucose level below 126 mg/dL and an HbA1c level below 6.5% for more than 6 months without anti-diabetic drugs. Odds ratios (ORs) of remission of type-2 diabetes were estimated using logistic-regression models. Results: A lower proportion of patients who had fatty liver detected by ultrasonography at baseline (8.7%, 167/1910) had remission of type-2 diabetes during the follow-up period than patients without fatty liver (13.1%, 86/657). Fatty liver at baseline was associated with a lower odds of remission of type-2 diabetes (multivariable-adjusted OR, 0.51; 95% CI, 0.37–0.72). A higher proportion of patients who had improvement of fatty liver had remission of type-2 diabetes (21.1%, 32/152) than patients with no improvement of fatty liver (7.7%, 129/1681). Improvement of fatty liver was associated with a higher odds of remission of type-2 diabetes (multivariable-adjusted OR, 3.08; 95% CI, 1.94–4.88). Conclusions: Over a follow-up period of approximate 2 years, remission of type-2 diabetes was less common in people with fatty liver detected by ultrasonography, and improvement of fatty liver was independently associated with type-2 diabetes remission.
KW - Cohort
KW - Diabetes Mellitus
KW - Reversal
KW - Steatosis
UR - http://www.scopus.com/inward/record.url?scp=85093974067&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85093974067&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2020.06.032
DO - 10.1016/j.cgh.2020.06.032
M3 - Article
C2 - 32565288
AN - SCOPUS:85093974067
SN - 1542-3565
VL - 19
SP - 556-564.e5
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 3
ER -